相关实验视频
Updated: Jan 9, 2026

07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
61.4K
鼻内胰岛素会影响大脑,但不会影响外围组织,瘦身,健康男性的葡萄糖吸收:一项正电子发射断层扫描研究
Aino Latva-Rasku1,2, Sanna Laurila1,3, Tomi Karjalainen1
1Turku PET Centre, University of Turku, Turku, Finland.
American journal of physiology. Endocrinology and metabolism
|December 5, 2025
概括
鼻内胰岛素 (INI) 在健康男性中没有影响周围葡萄糖代谢. 然而,NII确实导致大脑葡萄糖吸收的全球减少,这与之前的预期相反.
科学领域:
- 神经科学是一个神经科学.
- 代谢研究研究 代谢研究
- 内分泌学 在内分泌学.
背景情况:
- 人们越来越认识到胰岛素在大脑葡萄糖代谢中的作用.
- 以前的研究表明,鼻内胰岛素 (INI) 可能会影响周围代谢.
- 人类研究INI的系统性影响是有限的.
研究的目的:
- 研究INI对人类大脑和外围组织特异性葡萄糖吸收的影响.
- 为了确定INI是否增强或改变关键代谢组织中的葡萄糖代谢.
- 评估INI的影响与内脏脂肪组织之间的关系.
主要方法:
- 一项随机,单盲,交叉研究,涉及10名健康男性.
- 低剂量高胰岛素,高血糖结合鼻内胰岛素或安慰剂.
- 用2-deoxy-2[18F]fluoro-d-glucose进行正子发射断层扫描 (PET),以量化组织葡萄糖吸收.
- 计算机断层扫描 (CT) 用于组织体积和放射密度的评估.
主要成果:
- 在所有参与者中,鼻内胰岛素 (INI) 显著降低了所有参与者的全球脑糖摄取量.
- 大脑葡萄糖摄取量下降的程度与内脏脂肪组织相关.
- INI对骨肌肉,肝脏或脂肪组织的葡萄糖吸收没有显著影响.
结论:
- 一次剂量INI在瘦身,健康的男性中不会直接影响周围葡萄糖代谢.
- INI的核心效应伴随着大脑葡萄糖代谢的总体减少.
- 伊尼对新陈代谢的影响可能是特定于大脑而不是系统性增强.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Hormones Regulating Blood Glucose
6.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Insulin: Dosing Regimen and Adverse Effects
658
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
658
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572

